BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 30722725)

  • 1. CDK11
    Du Y; Yan D; Yuan Y; Xu J; Wang S; Yang Z; Cheng W; Tian X; Kan Q
    Cell Cycle; 2019 Feb; 18(4):452-466. PubMed ID: 30722725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth.
    Zhou Y; Han C; Li D; Yu Z; Li F; Li F; An Q; Bai H; Zhang X; Duan Z; Kan Q
    Sci Rep; 2015 May; 5():10433. PubMed ID: 25990212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of long noncoding RNA MALAT1 contributes to proliferation and metastasis in esophageal squamous cell carcinoma.
    Hu L; Wu Y; Tan D; Meng H; Wang K; Bai Y; Yang K
    J Exp Clin Cancer Res; 2015 Jan; 34(1):7. PubMed ID: 25613496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
    Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
    Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal lncRNA ZFAS1 regulates esophageal squamous cell carcinoma cell proliferation, invasion, migration and apoptosis via microRNA-124/STAT3 axis.
    Li Z; Qin X; Bian W; Li Y; Shan B; Yao Z; Li S
    J Exp Clin Cancer Res; 2019 Nov; 38(1):477. PubMed ID: 31775815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.
    Zeng H; Yang H; Song Y; Fang D; Chen L; Zhao Z; Wang C; Xie S
    Cell Death Dis; 2021 Nov; 12(11):1048. PubMed ID: 34741018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [MIR503HG promotes esophageal squamous cell carcinoma cell proliferation, invasion and migration via hsa-miR-503 pathway].
    Gong TY; Chen HY; Liu ZH
    Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1160-1167. PubMed ID: 36380664
    [No Abstract]   [Full Text] [Related]  

  • 9. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
    Fan T; Chen J; Zhang L; Gao P; Hui Y; Xu P; Zhang X; Liu H
    Mol Cancer; 2016 Mar; 15():23. PubMed ID: 26956728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential therapeutic effect of targeting glycogen synthase kinase 3β in esophageal squamous cell carcinoma.
    Bolidong D; Domoto T; Uehara M; Sabit H; Okumura T; Endo Y; Nakada M; Ninomiya I; Miyashita T; Wong RW; Minamoto T
    Sci Rep; 2020 Jul; 10(1):11807. PubMed ID: 32678196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TOPK promotes metastasis of esophageal squamous cell carcinoma by activating the Src/GSK3β/STAT3 signaling pathway via γ-catenin.
    Jiang Y; Zhang J; Zhao J; Li Z; Chen H; Qiao Y; Chen X; Liu K; Dong Z
    BMC Cancer; 2019 Dec; 19(1):1264. PubMed ID: 31888532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Cell-Derived Complement Component C1r Acts as a Prognostic Biomarker and Promotes Esophageal Squamous Cell Carcinoma Progression.
    Tang M; Zhao S; Ren L; Li Q; Li L; Wang C; Meng C; Chen Y; Hu W
    Front Biosci (Landmark Ed); 2024 Apr; 29(4):138. PubMed ID: 38682192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m
    Xiao D; Fang TX; Lei Y; Xiao SJ; Xia JW; Lin TY; Li YL; Zhai JX; Li XY; Huang SH; Jia JS; Tian YG; Lin XL; Cai KC; Sun Y
    Aging (Albany NY); 2021 Sep; 13(17):21497-21512. PubMed ID: 34491904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. m
    Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
    Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-1 suppresses the growth of esophageal squamous cell carcinoma in vivo and in vitro through the downregulation of MET, cyclin D1 and CDK4 expression.
    Jiang S; Zhao C; Yang X; Li X; Pan Q; Huang H; Wen X; Shan H; Li Q; Du Y; Zhao Y
    Int J Mol Med; 2016 Jul; 38(1):113-22. PubMed ID: 27247259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of SALL4 reduces tumorigenicity involving epithelial-mesenchymal transition via Wnt/β-catenin pathway in esophageal squamous cell carcinoma.
    He J; Zhou M; Chen X; Yue D; Yang L; Qin G; Zhang Z; Gao Q; Wang D; Zhang C; Huang L; Wang L; Zhang B; Yu J; Zhang Y
    J Exp Clin Cancer Res; 2016 Jun; 35(1):98. PubMed ID: 27329034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma.
    Zheng L; Zhao Z; Rong L; Xue L; Song Y
    J Genet Genomics; 2019 Oct; 46(10):477-488. PubMed ID: 31812473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RELT promotes the growth of esophageal squamous cell carcinoma by activating the NF-κB pathway.
    Yao W; Chen Q; Li S; Jia X; Xu L; Wei L
    Cell Cycle; 2021 Jul; 20(13):1231-1241. PubMed ID: 34121605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WISP2 exhibits its potential antitumor activity via targeting ERK and E-cadherin pathways in esophageal cancer cells.
    Chai DM; Qin YZ; Wu SW; Ma L; Tan YY; Yong X; Wang XL; Wang ZP; Tao YS
    J Exp Clin Cancer Res; 2019 Feb; 38(1):102. PubMed ID: 30808397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EIF3H promotes aggressiveness of esophageal squamous cell carcinoma by modulating Snail stability.
    Guo X; Zhu R; Luo A; Zhou H; Ding F; Yang H; Liu Z
    J Exp Clin Cancer Res; 2020 Aug; 39(1):175. PubMed ID: 32867821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.